<DOC>
	<DOCNO>NCT02162758</DOCNO>
	<brief_summary>This study design evaluate effect dexlansoprazole QD BID dose recurrence intestinal metaplasia ( IM ) subject achieved complete eradication Barrett 's esophagus ( BE ) high-grade dysplasia ( HGD ) follow radiofrequency ablation ( RFA ) .</brief_summary>
	<brief_title>Effect Dexlansoprazole 60 mg QD 60 mg BID Recurrence Intestinal Metaplasia Subjects Who Have Achieved Complete Eradication Barrett 's Esophagus With Radiofrequency Ablation</brief_title>
	<detailed_description>The drug test study call dexlansoprazole . The purpose study evaluate effect 12 month treatment dexlansoprazole 60 mg QD dexlansoprazole 60 mg BID recurrence IM participant achieve complete eradication intestinal metaplasia ( CEIM ) dysplasia ( CED ) Radiofrequency Ablation ( RFA ) . The study enroll approximately 150 patient . Participants randomly assign ( chance , like flip coin ) one two treatment group remain undisclosed patient study doctor study ( unless urgent medical need ) : - Dexlansoprazole 60 mg day placebo ( capsule look like study drug active ingredient ) day - Dexlansoprazole 60 mg twice day . All participant ask take one capsule twice day time day throughout study . This randomized , double-blind , multi-center , parallel group trial conduct North America . The overall time participate study 13 month . Participants make 5 visit clinic , undergo safety follow-up assessment 30 day last dose study drug .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>1 . Is male female age 18 80 year , inclusive . 2 . In opinion investigator , participant capable understand comply protocol requirement . 3 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 4 . Has history initial complete eradication intestinal metaplasia ( CEIM ) follow radiofrequency ablation ( RFA ) Barrett 's esophagus highgrade dysplasia within past 3 year . 5 . Had attain CEIM within 12 month receive first RFA treatment . 6 . Has endoscopic histologic confirm evidence CEIM prior randomization . 7 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 12 week last dose . 8 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study . 1 . Has evidence cardiovascular , pulmonary , central nervous system , hepatic , hematopoietic , renal , metabolic , endocrine gastrointestinal disease , serious allergy , asthma , allergic skin rash suggest clinically significant , uncontrolled underlying disease condition ( disease study ) , may impact ability participant participate potentially confound study result . 2 . Had previous ablative therapy modality RFA Barrett 's esophagus ( photodynamic therapy , multipolar electrical coagulation , argon plasma coagulation , laser treatment ) exception 3 treatment thermal/coagulation therapy focal residual disease follow otherwise successful RFA therapy . 3 . Has coexist disease affect esophagus ( eg , erosive esophagitis , esophageal varix , scleroderma , viral fungal infection , esophageal stricture ) , history radiation therapy cryotherapy esophagus , caustic physiochemical trauma sclerotherapy esophagus . 4 . Has know history eosinophilic esophagitis endoscopic finding suggestive eosinophilic esophagitis . 5 . Has active gastric duodenal ulcer within 4 week prior Day 1 . 6 . Has find his/her medical history , physical examination , safety clinical laboratory test give reasonable suspicion underlie disease might interfere conduct trial . 7 . Has history hypersensitivity allergy dexlansoprazole component dexlansoprazole proton pump inhibitor ( PPI ) ( include lansoprazole , omeprazole , rabeprazole , pantoprazole , esomeprazole ) antacid . 8 . Is required take exclude medication anticipate participant require treatment least one disallow concomitant medication study evaluation period specify Excluded Medications Treatments Section.. 9 . Has history malignant disease ( except basal cell carcinoma ) within 5 year prior Screening . 10 . Has condition may require inpatient surgery course study . 11 . Requires dilatation esophageal strictures and/or stricture prevent passage endoscope Screening endoscopy . Schatzki 's ring ( ring mucosal tissue near low esophageal sphincter ) acceptable . 12 . Is know acquired immunodeficiency syndrome . 13 . Has current clinical history ZollingerEllison syndrome hypersecretory condition . 14 . Has history gastric , duodenal esophageal surgery except simple oversew ulcer . A history gastric tube and/or percutaneous endoscopic gastrostomy ( PEG ) placement allow . 15 . Had acute upper gastrointestinal hemorrhage within 4 week prior endoscopy . 16 . Has donate lose â‰¥300 mL blood volume , undergone plasmapheresis , transfusion blood product within 90 day prior first dose study drug . 17 . Has know history alcohol abuse illegal drug use within past 12 month prior first dose study drug , unwilling agree abstain alcohol illegal drug use throughout study . 18 . If female , participant pregnant lactate intend become pregnant , within 30 day last dose study medication ; intend donate ova time period . 19 . If male , participant intend donate sperm course study within 30 day last dose study drug . 20 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study may consent assent duress . Students institution/research facility supervision , subordinate role , investigator also ineligible . 21 . In opinion investigator , unlikely comply protocol requirement unsuitable reason . 22 . Has previously randomize study receive least one dose double blind study drug treatment . 23 . Has receive investigational compound within 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>